secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001104659-24-024358
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q4 revenue $1.60B (+8% YoY); FY23 EPS $3.99; FY24 guidance $6.2-6.5B
----------------------------------------------------------------------------

- FY23 revenue $6.3B (+1% as-reported, +3% constant currency).
- FY23 diluted EPS $3.99, non-GAAP adjusted diluted EPS $4.14; Adj. EBITDA $1.9B (31% margin).
- Q4 revenue $1.60B (+8% YoY); Q4 non-GAAP adj. diluted EPS $0.88 (+9%).
- Biosimilars rev +49% (Hadlima >doubled); Women's Health +7% (Follistim +63% ex-FX).
- FY2024 guidance: revenue $6.2-6.5B, Adj. EBITDA margin 31-33%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/0001104659-24-024358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/tm246328d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-024358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer